Promoting Pediatric Drug Research and Labeling - Outcomes of Legislation.
N Engl J Med. 2019.
PMID: 31461599
No abstract available.
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2007 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 0 |
Search Results
4
results
Results by year
Citations
1 article found by citation matchingSearch results
Filters applied: . Clear all
Page 1
Promoting Pediatric Drug Research and Labeling - Outcomes of Legislation.
Bourgeois FT, Kesselheim AS.
Bourgeois FT, et al.
N Engl J Med. 2019 Aug 29;381(9):875-881. doi: 10.1056/NEJMhle1901265.
N Engl J Med. 2019.
PMID: 31461599
No abstract available.
Item in Clipboard
Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation.
Benning TJ, Shah ND, Inselman JW, Van Houten HK, Ross JS, Wyatt KD.
Benning TJ, et al.
Clin Trials. 2021 Dec;18(6):732-740. doi: 10.1177/17407745211030683. Epub 2021 Jul 16.
Clin Trials. 2021.
PMID: 34269090
BACKGROUND/AIMS: The Pediatric Research Equity Act and Best Pharmaceuticals for Children Act are intended to promote the conduct of clinical trials that generate pediatric-specific evidence about drug safety and efficacy. ...A median of 49 child …
BACKGROUND/AIMS: The Pediatric Research Equity Act and Best Pharmaceuticals for Children Act are intended to promote th …
Item in Clipboard
Incidence of Pediatric Cannabis Exposure Among Children and Teenagers Aged 0 to 19 Years Before and After Medical Marijuana Legalization in Massachusetts.
Whitehill JM, Harrington C, Lang CJ, Chary M, Bhutta WA, Burns MM.
Whitehill JM, et al.
JAMA Netw Open. 2019 Aug 2;2(8):e199456. doi: 10.1001/jamanetworkopen.2019.9456.
JAMA Netw Open. 2019.
PMID: 31418807
Free PMC article.
Data analysis was performed from November 12, 2018, to July 20, 2019. EXPOSURE: Cannabis products. MAIN OUTCOMES AND MEASURES: Incidence of RPC-reported cannabis exposure cases, both single substance and polysubstance, for the age group of 0 to 19 years, and cannabis pr …
Data analysis was performed from November 12, 2018, to July 20, 2019. EXPOSURE: Cannabis products. MAIN OUTCOMES AND MEASURES: Incide …
Item in Clipboard
Unlicensed and off-label use of medicines at a neonatology clinic in Italy.
Dell'Aera M, Gasbarro AR, Padovano M, Laforgia N, Capodiferro D, Solarino B, Quaranta R, Dell'Erba AS.
Dell'Aera M, et al.
Pharm World Sci. 2007 Aug;29(4):361-7. doi: 10.1007/s11096-006-9081-z. Epub 2007 Mar 10.
Pharm World Sci. 2007.
PMID: 17351821
OBJECTIVE: Many drugs used for children are not licensed or are used off-label. An increased risk of medication errors and unexpected adverse drug reactions (ADR) associated with off-label and unlicensed drug prescription has been reported. ...CONCLUSI …
OBJECTIVE: Many drugs used for children are not licensed or are used off-label. An increased risk of medication errors and unexpected …
Item in Clipboard
Cite
Cite